Register / Log In

Standard interferon regimen proves superior in high-risk melanoma patients

Tampa, Fla. — Adjuvant therapy with high-dose interferon induction administered for only four weeks did not show to improve relapse-free survival or overall survival in patients with resectable intermediate and high-risk melanoma, according to the results of a recent study discussed at the 2011 International Melanoma Congress in Tampa, Fla.

"Interferon is the standard adjuvant therapy used for high-risk melanoma patients with node positive disease. Shortening the therapeutic regimen down to just one month, unfortunately, does not show benefit in melanoma patients, underscoring the need for the longer-standing and approved one-year-long interferon treatment regimen," says Sanjiv S. Agarwala, M.D., chief, medical oncology and hematology, St. Luke's Cancer Center, Temple University School of Medicine, Bethlehem, Pa.

According to Dr. Agarwala, the current standard adjuvant therapy for melanoma in the United States is a year-long regimen of interferon comprised of two phases — a four-week, high-dose intravenous induction phase followed by a maintenance phase that is given at 11 months at a lower dose.

In the hopes of potentially reducing the sometimes significant toxicity associated with this treatment regimen as well as offering a more convenient therapeutic protocol for patients, Dr. Agarwala and colleagues conducted a multicenter study to see if just four weeks of high-dose interferon without the standard maintenance dose typically given at 11 months would be sufficient to show benefit in melanoma patients.

In February, the Centers for Medicare and Medicaid Services released a notice of proposed rulemaking titled Medicare and Medicaid Programs; Electronic Health Record Incentive Program — Stage 2. The proposal, which was issued in the Federal Register, outlines CMS' recommended guidelines for Stage 2 of meaningful use for the government's Electronic Health Records (EHR) Incentive Program.

Techniques to decrease the pain of botulinum toxin injections include mixing the toxin with bacteriostatic saline, using special cannulas designed for diabetics and injecting through follicles or pores wherever possible, says David M. Ozog, M.D.

A recent clinical trial on the use of adapalene and benzoyl peroxide gel 0.1 percent/2.5 percent (Epiduo, Galderma) for acne vulgaris in the pediatric population, demonstrated that it was a safe and effective treatment for preadolescents, according to Lawrence F. Eichenfield, M.D., principal investigator of the study, chief, pediatric and adolescent dermatology, and professor of pediatrics and medicine (dermatology), Rady Children's Hospital and University of California, San Diego.

Creams and emollients are relatively ineffective in treating ichthyosis, but vitamin A derivatives do prove to create responses in patients, according to the chief of pediatric dermatology at Phoenix Children's Hospital.

With conflicting evidence regarding the true risk of nonmelanoma skin cancers (NMSCs) in patients taking biologic drugs for psoriasis, Oscar Colegio, M.D., says physicians should consider treatment options for patients in this category on a case-by-case basis.